|
Contacts:
Nancy van Dillen
CONNECT
(858) 964-1319
nvandillen@ucsd.edu
Brian Brokowski
Fleishman-Hillard
(619) 237-7716
brokowsb@fleishman.com
SAN DIEGO (December 2, 2004) - CONNECT, UC San
Diego's program in technology and entrepreneurship, today announced
the winners for the 17th annual CONNECT Most Innovative New Product
(MIP) Awards, reinforcing the region's reputation for supporting
emerging technologies and encouraging creative product development.
The winners, announced at a luncheon at the Marriott Hotel & Marina,
were chosen from a field of 19 finalists by a distinguished panel of
judges representing leaders from San Diego's technology and life
science communities.
The 2004 MIP Award winners are:
Hardware:
Tarari, Inc. - Tarari RAX Content Processor (RAX-CP) - the fastest
product available for processing XML messages and documents, it
implements RAX in hardware to accelerate XPath expressions to query an
XML document.
Software:
BidShift, Inc. - BidShift v2.1 - Primarily helping to address the
current nursing shortage in healthcare, an innovative HCM software
tool with an auction-based, shift bidding application to assist
hospital administrators to optimize their staffing processes to
attract and retain staff and ultimately increase the quality of
patient care.
Telecommunications:
Entropic Communications - c.LINK-270 - a communications semiconductor
and software product that enables room-to-room networking at 270Mbps
without any changes to existing home wiring.
Life Science:
Ophthonix, Inc. - Z-View Aberrometer & iZon Wavefront-Guided Lenses -
a transformational wavefront measurement instrument designed
especially for the dispensing eye care practitioner to measure a
patient's unique optical fingerprint and achieve a patient's
refraction and lead to non-surgical vision optimization.
General Technology:
LIFE-SAFER, INC. -- The Personal Retriever - a patented "Rapid
Recovery" system device designed to overcome seven performance
deficiencies inherant in traditional drowning rescue tools by raising
the effectiveness of the on-scene responder and reducing the level of
risk.
Biotechnology R&D:
TargeGen - TG100-115 - a small molecule intravenous drug which reduces
tissue damage to the heart following a heart attack by suppressing
unwanted biochemical damage.
...more
|
